Fig. 3

The validation of the prognostic signature of DRLs. (A-B). Kaplan-Meier curves for overall survival (OS) in the training set (A) and testing set (B). (C-D). Distribution of the DRL-model-based risk score for the training set (C) and testing set (D). (E-F). Patterns of survival time and survival status ranked by risk score in the training set (E) and testing set (F). (G-H). Heatmap displaying the expression levels of six lncRNAs for glioma patients in the training set (G) and testing set (H)